CDX2 and Reg IV expression and correlation in gastric cancer

Dandan Chai  
Gansu Provincial Academic Institute for Medical Research

Huifen Du  
Gansu Provincial Academic Institute for Medical Research

Kesheng Li ( likesheng63@hotmail.com)  
Gansu Provincial Academic Institute for Medical Research  
https://orcid.org/0000-0002-6958-6551

Xueliang Zhang  
Gansu Provincial Cancer Hospital

Xiaoqin Li  
Gansu Provincial Cancer Hospital

Xiaoning Zhao  
Gansu Provincial Cancer Hospital

Xiaowen Lian  
Gansu Provincial Academic Institute for Medical Research

Yang Xu  
Gansu Provincial Academic Institute for Medical Research

Research article

Keywords: CDX2, Reg IV, correlation, migration, invasion, gastric cancer

DOI: https://doi.org/10.21203/rs.3.rs-56352/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Ectopic expression of CDX2 is associated with the development and progression of gastric cancer. Previous studies showed that CDX2 may be an upstream regulator of Reg IV expression in gastric cancer, and our previous report showed that Reg IV upregulated SOX9 expression and enhanced cell migration and invasion in gastric cancer cells. However, the regulatory roles of CDX2 have not been clarified in gastric cancer, and the correlation between CDX2 and Reg IV requires further study.

**Methods:** CDX2 and Reg IV were examined in gastric cancer specimens and paired adjacent tissues via real-time PCR and immunohistochemistry (IHC). The association between CDX2 and Reg IV was assessed using the χ²-test and Spearman's rank correlation. To verify their relationship, knockdown and exogenous expression of CDX2 or Reg IV were performed in AGS and MKN-45 gastric cancer cells, and their expression was subsequently analyzed via a real-time PCR and western blotting. Wound-healing and Transwell assays were used to examine migration and invasion in AGS and MKN-45 cells following CDX2 silencing or overexpression.

**Results:** A positive correlation was observed between CDX2 and Reg IV expression at the mRNA and protein levels in gastric cancer tissues. CDX2 silencing significantly downregulated Reg IV expression, and CDX2 overexpression significantly upregulated Reg IV expression in AGS and MKN-45 cells. Neither Reg IV silencing nor overexpression had any effect on CDX2 protein expression in AGS or MKN-45 cells, even though both affected the expression of CDX2 mRNA. Functionally, CDX2 silencing significantly inhibited cell migration and invasion, and CDX2 overexpression significantly promoted cell migration and invasion in AGS and MKN-45 cells.

**Conclusions:** Our findings demonstrate that CDX2 expression was positively correlated with that of Reg IV in gastric cancer, and CDX2 promoted cell migration and invasion through upregulation of Reg IV expression in AGS and MKN-45 cells.

**Background**

Gastric cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Caudal type homeobox 2 (CDX2) is an intestine-specific transcription factor belonging to the caudal-related homeobox gene family. Although CDX2 is not expressed in the gastric mucosa under normal conditions, its ectopic expression has been detected in gastric intestinal metaplasia (IM) and gastric carcinomas [18]. Reports have shown that CDX2 expression is related to IM of the stomach, lymphatic metastasis, survival, cell proliferation, migration, invasion, and multidrug resistance (MDR) in gastric carcinoma [1, 2, 6, 8–31]. Several studies showed that CDX2 expression may promote or contribute to IM in gastric cells [1, 2, 9–11]. The same results were observed in CDX2 transgenic mouse models [12–14] and long-term IM-induced invasive gastric carcinoma [15]. Moreover, increased CDX2 expression was associated with lymph node metastasis in gastric adenocarcinoma [16] and a more invasive phenotype in AGS cells [17]. In addition, CDX2 overexpression promoted the development of
MDR in SGC–7901/DDP (cisplatin-resistant) and BGC–823/5-FU (5-fluorouracil-resistant) human gastric cancer cells in vitro and in vivo [18]. Alternatively, CDX2 silencing significantly inhibited the growth of MGC–803 human gastric cancer cells [19] and reversed the progression of MDR in SGC–7901/DDP cells in vitro and in vivo [20]. These studies suggest that CDX2 may possess oncogenic activity. Conversely, several studies have indicated that CDX2 may act as a tumor suppressor. Reports have shown that CDX2 expression is negatively correlated with lymph node metastasis, tumor invasion, and survival in gastric cancer [6–8, 21–25]. Additionally, CDX2 overexpression inhibited proliferation, migration, and invasion in human gastric cancer cell lines (MGC–803, MKN–45, and BGC–823) [26–31]. Alternatively, CDX2 silencing promoted migration and invasion in NCI-N87 cells [26]. However, Dang et al. concluded that disruption of CDX2 did not significantly affect tumorigenic potential [32]. Taken together, these conflicting results show that the regulatory roles of CDX2 in gastric cancer remain unclear.

Regenerating islet-derived family member 4 (REG4) encodes the Reg IV protein and is a member of the REG gene family, which belongs to the calcium-dependent lectin superfamily. Reg IV is a small secretory protein that is highly expressed in gastrointestinal malignancies, indicating that Reg IV may have a prognostic or predictive value in these cancers [33–35]. Moreover, several studies revealed that Reg IV expression is related to metastasis, migration, proliferation, apoptosis, and drug resistance in gastric cancer [36–40]. Wang et al. established two stably transfected cell lines (SGC–7901/Reg IV and MKN–45/Reg IV) and suggested that Reg IV interacts with G protein-coupled receptor 37 (GPR37) in gastric cancer cells to promote peritoneal metastasis by increasing cell adhesion [36]. Huang et al. reported that Reg IV promoted the growth, proliferation, and migration of MKN–45 cells through the Akt pathway [37]. Recent studies showed that Reg IV inhibited apoptosis through activation of Erk/Bim signaling, thereby enhancing the resistance of AGS and SGC–7901 cells to 5-FU [38]. Another study showed that the single-chain antibody against Reg IV significantly inhibited cell proliferation and enhanced 5-FU-induced cell death in MKN–45 and AGS cells [39]. These findings indicate that Reg IV may be a tumor-promoting factor in gastric cancer. Our previous study suggested that Reg IV upregulated SRY related high-mobility group box 9 (SOX9) expression and enhanced cell migration and invasion in MKN–45 and AGS cells [40]. Additionally, CDX2 may be an upstream regulator of Reg IV expression in gastric cancer [41, 42]. Therefore, we speculate that CDX2 may regulate the migration and invasion of gastric cancer cells through Reg IV/SOX9 signaling. In this study, we investigated the correlation between CDX2 and Reg IV in gastric cancer tissues and cell lines, and the effect of CDX2 on migration and invasion in gastric cancer cells in vitro.

Methods

Tissue samples

Formalin-fixed paraffin-embedded tissue specimens from 102 primary gastric cancer patients who received surgery in the Gansu Provincial Cancer Hospital from March 2014 to April 2015 were subjected to immunohistochemical analysis. Another 93 cases and paired adjacent tissues were obtained from surgical specimens resected from patients who had not received chemotherapy or radiotherapy prior to
surgery. The samples were immediately frozen in liquid nitrogen and stored at −80°C for preparation of total RNA. Detailed clinicopathologic characteristics of the patients were listed in Table 1. All of the patients gave written informed consent, and the procedures involving human tissues were approved by the Medical Ethics Committee of Gansu Provincial Academic Institute for Medical Research.

| Clinicopathologic parameter | IHC staining | Real-time PCR |
|-----------------------------|--------------|---------------|
| All cases                   | 102          | 93            |
| Age (years)                 |              |               |
| < 60                        | 61           | 48            |
| ≥ 60                        | 41           | 45            |
| Gender                      |              |               |
| Male                        | 76           | 70            |
| Female                      | 26           | 23            |
| Depth of invasion           |              |               |
| T1 + T2                     | 27           | 22            |
| T3 + T4                     | 75           | 71            |
| Lymph node metastasis       |              |               |
| Negative                    | 32           | 22            |
| Positive                    | 70           | 71            |
| TNM staging                 |              |               |
| I + II                      | 43           | 29            |
| III + IV                    | 59           | 64            |

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded tissue specimens were obtained and handled according to standard procedures. Serial 4-μm sections were prepared and stained using biotin-streptavidin HRP detection systems (ZSGB-BIO, Beijing, China) with the following primary antibodies: CDX2 (1:300; Bioss, Beijing, China), Reg IV (1:300; Bioss). Immunoreactivity was visualized with 3,3'-diaminobenzidine (DAB). Nuclei were lightly counterstained with hematoxylin. Staining intensity was scored using the following scale: negative, 0; weak, 1; moderate, 2; and strong, 3. The proportion of stained cells was scored using the following scale: < 5%, 0; 5%–25%, 1; 25%–50%, 2; 50%–75%, 3; and > 75%, 4. The scores for staining intensity and proportion of positive cells were multiplied. For the purpose of statistical analysis, tumors with a final staining score ≥ 3 were considered to be positive. Images were acquired using RPT-PathQC system software (Logene, Wuxi, China) under an Olympus BX43 microscope (200× magnification).

**Total RNA extraction and real-time PCR**

Total RNA was extracted using RNAiso Plus (Takara, Dalian, China) and reverse-transcribed using PrimeScript RT Master Mix (Takara) according to the manufacturer's protocol. We amplified cDNA samples using SYBR Premix Ex Taq II (Tli RNaseH Plus) (Takara) and determined the cycle threshold (Ct).
Sequences of the primers used are shown in Table 2. Relative mRNA expression levels were calculated using the $2^{-\Delta\Delta C_t}$ method and the Ct values were normalized using GAPDH as the internal control.

**Table 2** Real-time PCR primers

| Primers | Forward                        | Reverse                                      |
|---------|--------------------------------|----------------------------------------------|
| CDX2    | 5'-AAGTGAAAACCAGGACGAAAGA-3'   | 5'-GGATGGGTGATGTAGCGACTGTA-3'               |
| Reg IV  | 5'-CAGATCCTGGTCTGGCAAGT-3'     | 5'-ATTCGTTGCTGCTCAAAGTT-3'                  |
| GAPDH   | 5'-GCACCGTCAAGGCTGAGAAC-3'     | 5'-TGGTGAAGACGCCAGTGGA-3'                   |

**Cell culture**

The human gastric cancer AGS cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and MKN–45 cells were kindly provided by Prof. Hongyun Guo from Gansu Provincial Academic Institute for Medical Research. Cells were cultured in high-glucose DMEM (Thermo Fisher Scientific, Shanghai, China) with 10% fetal bovine serum (FBS, Minhai Biotechnology Co., Ltd., Beijing, China) at 37°C with 5% CO$_2$.

**Silencing of CDX2 and Reg IV genes by siRNAs**

Chemically synthetic siRNAs for human CDX2, Reg IV, and a nontargeting control siRNA were purchased from GenePharma Co., Ltd. (Shanghai, China). Briefly, cells grown on six-well plates were transfected using 10–40 nM siRNA and 7.5 µL Lipofectamine RNAiMAX (Thermo Fisher Scientific) per well, and the medium was changed after 6 h. The knockdown efficiency was evaluated 48 h later via real-time PCR and western blotting. The sense and antisense strands of siRNAs are listed in Table 3.

**Table 3** siRNA sequences
| Name   | Sequence                                    |
|--------|---------------------------------------------|
| siR-CDX2-1 | Sense, 5'-GACAAGGACGUGAGCAUGUTT-3'  
Antisense, 5'-ACAUGCUCACGUCCUUUGUCTT-3' |
| siR-CDX2-2 | Sense, 5'-GACAAAUAUCGAGUGGUGUTT-3'  
Antisense, 5'-ACACCAUCAGAUUUUGUCTT-3' |
| siR-CDX2-3 | Sense, 5'-CAUCACCAUCCGGAGAAAAT-3'  
Antisense, 5'-UUUCCUCCGGAGUGAUGTT-3' |
| siR-Reg IV | Sense, 5'-CUUCAGGAAGCUGAGGACTT-3'  
Antisense, 5'-GUUCCUCAGCUUCCGAAGTT-3' |
| siR-NC    | Sense, 5'-UUCUCCGAACGUGUCAGUTT-3'  
Antisense, 5'-ACGUGACACGUCCGAGATT-3' |

**Overexpression of CDX2 and Reg IV genes**

The mammalian pEGFP-C1-Reg IV expression plasmid was described previously [40]. The CDX2 expression plasmid was constructed by inserting the coding sequence region of the human CDX2 cDNA into the pcDNA4/TO vector using the Hind II and Bam HI endonucleases (TaKaRa) and verified by DNA sequencing (GENEWIZ, Suzhou, China). The CDX2 primer sequences were as follows: forward, 5'-CCC AAGCTT GCCACCATGTACGTGAGCTAC–3'; reverse, 5'-CGGGAATCTCAGGAGCTGAGCACGCTGAGCTAC-3'. The recombinant vector was designated pcDNA4/TO-CDX2, which was subsequently extracted with an E. Z. N. A. Endo-Free Plasmid Mini Kit (Omega Bio-Tek, Norcross, GA, USA). For plasmid transfection experiments, cells were transiently transfected using Lipofectamine 3000 (Thermo Fisher Scientific), as recommended by the manufacturer. Briefly, cells were seeded in six-well plates at a density of 4.25 × 10^5 per well. After 24 h, cells were transfected using 2.5 μg plasmids and 7.5 μL Lipofectamine 3000 per well and medium was changed after 6 h. The empty vectors were used as the control. At 36 h post-transfection, the cells were lysed and analyzed using real-time PCR and western blotting.

**Western blotting**

Total proteins were extracted using the Tissue or Cell Total Protein Extraction Kit (Sangon Biotech, Shanghai, China) and quantified with the BCA Protein Assay Kit (Sangon Biotech). Proteins (60–100 μg per lane) were separated via 12% SDS-PAGE and transferred to a PVDF membrane. After blocking with TBST containing 5% nonfat milk powder, the membranes were incubated with primary antibodies against CDX2 (1:1000; Abcam, Shanghai, China), Reg IV (1:1000; Cell Signaling Technology, Shanghai, China), and β-actin (1:1000; Santa Cruz Biotechnology, Shanghai, China) at 4°C overnight. After washing with TBST, the membranes were incubated with the corresponding HRP-conjugated secondary antibody (Santa Cruz Biotechnology) at room temperature for 90 min. Immunoreactive bands were visualized with
SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific) and recorded with a ChemiDoc™ XRS+ (Bio-Rad). Signal intensities were subsequently quantified using Image Lab quantification software (Bio-Rad, Hercules, CA, USA).

**Wound-healing assay**

Cells were seeded in six-well plates, and transfected with siRNAs, pcDNA4/TO-CDX2 or pEGFP-C1-Reg IV. When the cells reached 90% confluence, monolayers were scratched with a 200 μL pipette tip to create wounds and then rinsed twice with DMEM to remove suspended cells. Fresh DMEM with 1% FBS was added to the wounded cell layer, and the wound healing process was monitored at the indicated times (0, 24 and 36 h for AGS cells; 0, 24, 48 and 72 h for MKN–45 cells) with an inverted light microscope (Olympus CKX41) at 100× magnification. Image J software was used to calculate the scratch area.

**Transwell Assay**

Transwell invasion and migration assays were performed using 24-well Falcon Cell Culture Inserts (8 μm PET track-etched membrane, Corning, USA). Cells (1 × 10⁵) were seeded into the upper chamber in serum-free DMEM. For invasion assays, Matrigel Matrix (Corning, USA) was diluted in serum-free DMEM to a final concentration of 100–150 μg/mL. The insert was then coated with the Matrigel and incubated at 37°C overnight prior to the invasion assay. DMEM (500 μL) with 20% FBS was added to the lower chamber and cells were further incubated at 37°C in 5% CO₂ for 24 h (AGS) or 48 h (MKN–45). The invasive cells on the lower surface of the membrane were fixed and stained with a crystal violet solution. Cells were counted in five random fields/well under a light microscope (Olympus CKX41) at 200× magnification. Migration assay was performed under the same conditions as the invasion assay described above, except that the insert was not coated with Matrigel and DMEM with 10% FBS was added to the lower chamber.

**Statistical analysis**

The association between CDX2 and Reg IV in gastric cancer tissues was analyzed using χ²-test and Spearman’s rank correlation. Data from cell-based studies are presented as mean ± SD and statistically analyzed by a two-tailed Student's t-test. All of the statistical analyses were carried out using SPSS 23.0, and p < 0.05 (*) or p < 0.01 (**) were considered to be statistically significant.

**Results**

CDX2 expression was positively correlated with Reg IV expression in gastric cancer tissues
To explore the possible relationship between CDX2 and Reg IV in gastric cancer tissues, mRNA and protein levels were measured by real-time PCR and IHC. The samples were divided into two groups based on the relative expression of mRNA in the 93 cases: low (≤2) and high expression (>2). A high expression of CDX2 mRNA was found in 31 of the 93 cases, and a low expression was found in 62 of the 93 cases. Low CDX2 expression was frequently observed in gastric cancer tissues with low Reg IV expression (72.6%, 45 of 62 cases), and high CDX2 expression was frequently observed in tissues with high Reg IV expression (67.7%, 21 of 31 cases; p = 0.000 by χ²-test; Table 4). Correlation analysis further showed that the expression of CDX2 mRNA was positively associated with that of Reg IV mRNA in gastric cancer tissues (r = 0.387, p = 0.000; Table 4). Furthermore, we examined protein expression in the 102 cases, and representative images of the IHC results are shown in Fig. 1. CDX2 was mainly found in the nucleus with cytoplasmic staining occasionally observed. Reg IV was detected mainly in the cytoplasm of tumor cells. CDX2 was negative in 67 cases and positive in 35 cases, and CDX2 expression was associated with Reg IV expression (p = 0.032 by χ²-test; Table 5). Further analysis showed that the expression of the CDX2 protein was positively associated with that of the Reg IV protein in gastric cancer tissues (r = 0.334, p = 0.001; Table 5). These results suggest that CDX2 expression positively correlates with Reg IV expression in gastric cancer tissues.

**Table 4** Correlation between CDX2 mRNA and Reg IV mRNA in gastric cancer tissues

| Reg IV  | Total | χ²  | p    | r     | p     |
|---------|-------|-----|------|-------|-------|
|         |       |     |      |       |       |
| Low     | 45    | 17  | 62   | 13.906| 0.000**| 0.387 | 0.000**|
| (72.6%) | (27.4%)|     |      |       |       |
| High    | 10    | 21  | 31   |       |       |       |
| (32.3%) | (67.7%)|     |      |       |       |

**Table 5** Correlation between CDX2 protein and Reg IV protein in gastric cancer tissues

| Reg IV  | Total | χ²  | p    | r     | p     |
|---------|-------|-----|------|-------|-------|
|         |       |     |      |       |       |
| Low     | 36    | 31  | 67   | 4.603 | 0.032*| 0.334 | 0.001**|
| (53.7%) | (46.3%)|     |      |       |       |
| High    | 11    | 24  | 35   |       |       |       |
| (31.4%) | (68.6%)|     |      |       |       |
CDX2 silencing downregulated Reg IV expression in gastric cancer cells

To confirm whether CDX2 regulates Reg IV expression in gastric cancer cells, CDX2 expression was knocked down via RNA interference (RNAi). Measurement of the relative CDX2 mRNA expression level at 48 h post-transfection with the three CDX2 siRNAs showed that siR-CDX2–3 produced an optimal interference effect and CDX2 mRNA levels decreased by 86.0% in AGS cells (Fig. 2a). siR-CDX2–3 significantly reduced the mRNA (p = 0.000) and protein (p = 0.003) levels of Reg IV in AGS cells (Fig. 2a–b). In MKN–45 cells, siR-CDX2–1 achieved the highest knockdown effect. Reg IV mRNA (p = 0.001) and protein (p = 0.007) levels were also decreased in the CDX2 knockdown group compared with the control group (Fig. 2c–d). These results indicate that the silencing of CDX2 led to the downregulation of Reg IV in gastric cancer cells.

CDX2 overexpression upregulated Reg IV expression in gastric cancer cells

To further confirm the regulation of Reg IV by CDX2 in gastric cancer cells, cells were transfected with pcDNA4/TO-CDX2 or pcDNA4/TO (control) for 36 h and CDX2 expression was analyzed via real-time PCR and western blotting. Fig. 3a and 3c shows that CDX2 mRNA levels increased by 101.8-fold (AGS, p = 0.000) and 301153.3-fold (MKN–45, p = 0.000). The western blotting results further verified the overexpression of CDX2 protein in AGS (p = 0.000) and MKN–45 (p = 0.000) cells (Fig. 3b and 3d). We found that Reg IV mRNA and protein levels increased after CDX2 overexpression in AGS and MKN–45 cells (p < 0.01; Fig. 3ad). These results suggest that the overexpression of CDX2 led to the upregulation of Reg IV in gastric cancer cells.

Reg IV did not affect CDX2 expression in gastric cancer cells

To investigate the effect of Reg IV on CDX2 in gastric cancer cells, Reg IV was silenced or overexpressed. siR-Reg IV, which had a significant silencing effect in our previous study [1], was transiently transfected into cells for 48 h. Real-time PCR analysis showed that Reg IV mRNA levels decreased by 79.5% (AGS) and 90% (MKN–45) (p < 0.01; left panels of Fig. 4ab). The western blotting results also demonstrated that siR-Reg IV significantly reduced Reg IV expression compared with the control groups (p < 0.01; middle and right panels of Fig. 4ab). Although the CDX2 mRNA level was downregulated (p = 0.000), the protein level did not change (p = 0.274) following Reg IV silencing in AGS cells (Fig. 4a). However, Reg IV silencing had no effect on CDX2 mRNA and protein levels in MKN–45 cells (p > 0.05; Fig. 4b). These results suggest that Reg IV silencing had no effect on CDX2 expression in gastric cancer cells.

Cells were also transfected with pEGFP-C1-Reg IV or pEGFP-C1 (control), and the expression of Reg IV was validated by real-time PCR and western blotting. Fig. 4c shows that Reg IV mRNA levels increased by 526.1-fold (AGS) and 3478357.1-fold (MKN–45) (p < 0.01). To further determine whether the Reg IV
protein was overexpressed, we detected the fusion protein (EGFP-Reg IV; ~ 41 KDa) of EGFP (27 KDa) and Reg IV (14 KDa) via western blotting using the Reg IV antibody. The results showed that EGFP-Reg IV was expressed when AGS and MKN–45 cells were transfected with pEGFP-C1-Reg IV (Fig. 4cd). Moreover, the endogenous Reg IV level was significantly upregulated in pEGFP-C1-Reg IV-transfected AGS cells (Fig. 4c). However, CDX2 mRNA and protein levels were unchanged following Reg IV overexpression in AGS cells (p > 0.05; Fig. 4c). Although Reg IV overexpression downregulated CDX2 mRNA levels in MKN–45 cells (p = 0.000), protein expression did not change (p = 0.154; Fig. 4d). These results indicate that Reg IV overexpression had no effect on CDX2 expression in gastric cancer cells.

**CDX2 promoted the migration and invasion of gastric cancer cells**

To determine the roles of CDX2 in the motility of AGS and MKN–45 cells, wound-healing, Transwell migration, and Matrigel invasion assays were performed following CDX2 silencing or overexpression. In the wound-healing assay, migration of AGS cells was significantly reduced after CDX2 silencing in comparison with the control group (p = 0.002 for 24 h, p = 0.000 for 36 h; Fig. 5a). Alternatively, cell migration was significantly increased after CDX2 overexpression (p = 0.047 for 24 h, p = 0.008 for 36 h; Fig. 5b). Because MKN–45 cells migrated very slowly, the wound healing process was monitored for 72 h. Consistent with the findings in AGS cells, knockdown of CDX2 dramatically inhibited the migration of AGS cells (p < 0.01; Fig. 5c) while overexpression of CDX2 significantly increased migration, especially after 48 h (p = 0.003) and 72 h (p = 0.031) (Fig. 5d). Moreover, the Transwell migration assay showed that CDX2 silencing significantly reduced the number of AGS cells that migrated from the upper surface to the lower surface of the inserts (p = 0.009; Fig. 5e), and CDX2 overexpression had the opposite effect (p = 0.014; Fig. 5f). Similar results were also observed in MKN–45 cells (Fig. 5g–h). Therefore, these data indicate that CDX2 promoted the migration of gastric cancer cells.

We further assessed the impact of CDX2 on the invasive properties of AGS and MKN–45 cells using Matrigel-coated inserts. Compared with the control group, the number of cells that passed through the Matrigel-coated membranes reduced by 81.0% in AGS cells transfected with siR-CDX2–3 (p = 0.000; Fig. 5e). However, CDX2 overexpression resulted in the opposite effect (p = 0.000; Fig. 5f). Consistently, CDX2 silencing inhibited the invasion of MKN–45 cells (p = 0.015; Fig. 5g), and CDX2 overexpression markedly increased invasion (p = 0.000; Fig. 5h). These results show that CDX2 promoted the invasion of gastric cancer cells.

**Discussion**

Gastric cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancer deaths in men and women worldwide [43]. It is a complex, heterogeneous, and multifactorial disease with different phenotypes [44]. Most gastric cancers are adenocarcinomas that can be histologically divided into intestinal, diffuse, mixed, and indeterminate subtypes and vary in morphology, epidemiology, progression pattern, genetics, and clinical type. The most common subtype is intestinal, which occurs in
approximately 54% of cases. Under normal conditions, CDX2 expression is restricted to the intestine. However, it is ectopically expressed in IM lesions of the stomach and intestinal-type gastric carcinoma [18]. Several studies have reported that CDX2 acts as a tumor suppressor in gastric cancer [6–8, 21–31]. However, others consider CDX2 an oncogene in gastric cancer [1, 2, 9–20]. These contradictory findings imply that CDX2 plays a complex regulatory role in gastric cancer. It was reported that Reg IV promoted tumor cell proliferation, metastasis, and migration and inhibited apoptosis in gastric cancer [36–39]. Collectively, although CDX2 and Reg IV are involved in the development and progression of gastric cancer, the regulatory correlation between CDX2 and Reg IV in gastric cancer remains unclear.

Results from this study demonstrated the following: First, there was a significantly positive correlation between the expression of CDX2 and Reg IV at the mRNA and protein levels in gastric cancer tissues. Previous studies have shown that CDX2 expression is associated with Reg IV expression [41, 45]. Yasui et al. reported that all of the Reg IV positive cells were also positive for CDX2 in both IM and gastric cancer; however, CDX2 positive cells were not consistently positive for Reg IV. This indicates that CDX2 might be an upstream regulator of Reg IV expression [41]. Another recent study showed that Reg IV expression was observed in all CDX2 positive cases of ovarian mucinous cancer [45]. Our study further demonstrated that CDX2 expression was positively correlated with Reg IV expression in gastric cancer tissues. Second, CDX2 upregulated Reg IV expression in gastric cancer cells. Previous studies demonstrated that Reg IV expression was induced by glioma-associated oncogene homolog 1 (GLI1) in pancreatic cancer [46] or by growth factors including transforming growth factor-α (TGF-α), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF) in colon cancer [47]. In the present study, Reg IV expression was also positively regulated by CDX2 in gastric cancer cells. Consistent with our findings, previous studies reported that Reg IV expression was induced by CDX2 overexpression in OMC-3 ovarian mucinous carcinoma cells and HT-29 colon cancer cells [42, 45] and suppressed by CDX2 siRNAs in HSC-39 gastric cancer cells [42]. Third, Reg IV had no effect on CDX2 expression in gastric cancer cells. SOX9 is a transcription factor which belongs to the SOX family and was induced by Reg IV in MKN-28, MKN-45, and AGS gastric cancer cells [40, 41]. CDX2 is also a transcription factor; however, silencing and overexpression of Reg IV did not affect CDX2 expression in AGS and MKN-45 cells. Fourth, CDX2 promoted migration and invasion of gastric cancer cells. The same research group has shown that CDX2 siRNA significantly inhibited cell proliferation, caused G0/G1 phase cell cycle arrest, induced apoptosis, and decreased migration and invasion in MGC-803 cells [19], whereas CDX2 overexpression produced results similar to those of CDX2 siRNA in MGC-803 cells [28], suggesting that CDX2 may play a dual role in the regulation of cell growth and death in MGC-803 cells. However, another study showed that CDX2 overexpression suppressed cell migration and invasion in MGC-803 cells and that CDX2 silencing promoted migration and invasion in NCI-N87 cells [26], indicating that CDX2 may inhibit migration and invasion of gastric cancer cells. Moreover, another report showed that ectopic expression of CDX2 reduced migration and invasion in MKN-45 cells [29], which is contrary to our findings in MKN-45 cells. The inconsistency in these results may be due to the different gastric cancer cell lines used in the studies. We previously found that Reg IV overexpression upregulated SOX9 and promoted migration and invasiveness of tumor cells, while Reg IV silencing produced opposite results. In
addition, SOX9 silencing inhibited the migration and invasion in MKN–45 and AGS cells, demonstrating that Reg IV may promote invasion and migration of MKN–45 and AGS cells through upregulation of SOX9 in AGS and MKN–45 cells [40]. In this study, CDX2 overexpression upregulated Reg IV expression and enhanced migration and invasion and CDX2 silencing downregulated Reg IV expression and suppressed migration and invasion in AGS and MKN–45 cells. These results demonstrate that CDX2 may promote cell migration and invasion through upregulation of Reg IV/SOX9 signaling in AGS and MKN–45 cells. Nevertheless, our and other studies also showed that silencing of SOX9 upregulated Reg IV protein expression in AGS, MKN–45, and MKN–74 cells [40, 41]. Furthermore, a previous report concluded that SOX9 also inhibited CDX2 protein expression both in intestinal adenocarcinoma cells *in vitro* and in a nude mouse xenograft tumor model [48]. Thus, we speculate that the aberrant expression of SOX9 may trigger negative feedback regulation on CDX2 and Reg IV in gastric cancer cells. Specifically, the ectopic expression of CDX2 may increase Reg IV and SOX9 levels, leading to the enhancement of migration and invasion. When SOX9 is increased to a certain level, it may conversely suppress the expression of CDX2 and Reg IV, resulting in a reduction of migration and invasion of gastric cancer cells. Further studies are needed to confirm these hypotheses.

**Conclusions**

Our study demonstrated that CDX2 expression was positively correlated with that of Reg IV in gastric cancer. Moreover, CDX2 promoted the migration and invasion of gastric cancer cells (AGS and MKN–45) through upregulation of Reg IV expression. Consequently, CDX2 may have considerable potential as a novel therapeutic target for gastric cancer.

**Abbreviations**

IHC: Immunohistochemistry; CDX2: Caudal type homeobox 2; IM: Intestinal metaplasia; MDR: Multidrug resistance; REG4: Regenerating islet-derived family member 4; GPR37: G protein-coupled receptor 37; SOX9: SRY related high-mobility group box 9; Ct: cycle threshold; FBS: fetal bovine serum; GLI1: Glioma-associated oncogene homolog 1; TGF-α: Transforming growth factor-α; EGF: Epidermal growth factor; bFGF: Basic fibroblast growth factor; HGF: Hepatocyte growth factor

**Declarations**

**Ethics approval and consent to participate**

Patient samples were collected with written informed consent in accordance with the guidelines of the Declaration of Helsinki. All procedures involving human tissues were approved by the Medical Ethics Committee of Gansu Provincial Academic Institute for Medical Research (A201803160008, 16 March 2018).

**Consent for publication**
Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Natural Science Foundation of Gansu Province (18JR3RA063).

Authors’ contributions

CDD performed all experiments and data analysis, and generated the first draft of the manuscript. DHF designed and organized the study. LKS designed the study and revise the manuscript. ZXN provided fresh tumor tissues from patients. LXQ provided paraffin-embedded sections and participated in IHC. ZXL, LXW and XY participated in data analysis. All authors read and approved the final manuscript.

Acknowledgments

We would like to thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

References

1. Yu JH, Zheng JB, Qi J, Yang K, Wu YH, Wang K, et al. Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway. Int J Oncol. 2019;54(3):879–92.

2. Zhou H, Ni Z, Li T, Su L, Zhang L, Liu N, et al. Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2. Oncol Lett. 2018;15:7617–24.

3. Bornschein J, Tóth K, Selgrad M, Kuester D, Wex T, Molnár B, et al. Dysregulation of CDX1, CDX2 and SOX2 in patients with gastric cancer also affects the non-malignant mucosa. J Clin Pathol. 2013;66:819–22.

4. Peleteiro B, Lunet N, Wen X, Afonso LP, Mendes N, Barros R, et al. Association between environmental factors and CDX2 expression in gastric cancer patients. Eur J Cancer Prev. 2012;21:423–31.
5. Kang JM, Lee BH, Kim N, Lee HS, Lee HE, Park JH, et al. CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. J Korean Med Sci. 2011;26:647–53.

6. Park DY, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, Zukerberg LR, et al. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol. 2010;23:54–61.

7. Ge J, Chen Z, Wu S, Yuan W, Hu B, Chen Z. A clinicopathological study on the expression of cadherin–17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma. Clin Oncol. 2008;20:275–83.

8. Ha Kim G, Am Song G, Youn Park D, Han Lee S, Hyun Lee D, Oh Kim T, et al. CDX2 expression is increased in gastric cancers with less invasiveness and intestinal mucin phenotype. Scand J Gastroenterol. 2006;41:880–6.

9. Barros R, Pereira B, Duluc I, Azevedo M, Mendes N, Camilo V, et al. Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines. J Pathol. 2008;215:411–20.

10. Asano N, Imatani A, Watanabe T, Fushiya J, Kondo Y, Jin X, et al. Cdx2 expression and intestinal metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses. Cancer Res. 2016;76:1135–45.

11. Li Q, Zhu Y, Liu J, Yu X, Chen M, Dong N, et al. HpSlyD inducing CDX2 and VIL1 expression mediated through TCTP protein may contribute to intestinal metaplasia in the stomach. Sci Rep. 2017;7:2278.

12. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology. 2002;122:689–96.

13. Mutoh H, Hakamata Y, Sato K, Eda A, Yanaka I, Honda S, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun. 2002;294:470–9.

14. Mutoh H, Sakurai S, Satoh K, Osawa H, Hakamata Y, Takeuchi T, et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut. 2004;53:1416–23.

15. Mutoh H, Sakurai S, Satoh K, Tamada K, Kita H, Osawa H, et al. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res. 2004;64:7740–7.

16. Samadani AA, Nikbakhsh N, Taheri H, Shafae S, Fattahi S, Pilehchian Langroudi M, et al. CDX1/2 and KLF5 expression and epigenetic modulation of sonic hedgehog signaling in gastric adenocarcinoma. Pathol Oncol Res. 2019;25:1215–22.

17. Song X, Chen HX, Wang XY, Deng XY, Xi YX, He Q, et al. H. pylori-encoded CagA disrupts tight junctions and induces invasiveness of AGS gastric carcinoma cells via Cdx2-dependent targeting of Claudin–2. Cell Immunol. 2013;286:22–30.

18. Yan LH, Wei WY, Cao WL, Zhang XS, Xie YB, Xiao Q. Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance. Am J Cancer Res. 2014;5:321–32.
19. Wang XT, Xie YB, Xiao Q. siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC–803 cells. World J Gastroenterol. 2012;18:1903–14.

20. Yan LH, Wang XT, Yang J, Lian C, Kong FB, Wei WY, et al. Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation. World J Gastroenterol. 2013;19:4155–65.

21. Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, et al. CD44v6, MMP–7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 2009;22:745–55.

22. Qin R, Wang NN, Chu J, Wang X. Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions. World J Gastroenterol. 2012;18:3296–302.

23. Wang XT, Wei WY, Kong FB, Lian C, Luo W, Xiao Q, et al. Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures. J Exp Clin Cancer Res. 2012;31:98.

24. Masood MA, Loya A, Yusuf MA. CDX2 as a prognostic marker in gastric cancer. Acta Gastroenterol Belg. 2016;79:197–200.

25. Saito M, Okayama H, Saito K, Ando J, Kumamoto K, Nakamura I, et al. CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer. Oncol Lett. 2017;14:6184–90.

26. Liu YQ, Bai ZG, Ma XM, Zhang ZT. CDX2 inhibits invasion and migration of gastric cancer cells by phosphatase and tensin homologue deleted from chromosome 10/Akt signaling pathway. Chin Med J (Engl). 2015;128:1065–71.

27. Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR–9 downregulates CDX2 expression in gastric cancer cells. Int J Cancer. 2011;129:2611–20.

28. Xie Y, Li L, Wang X, Qin Y, Qian Q, Yuan X, et al. Overexpression of Cdx2 inhibits progression of gastric cancer in vitro. Int J Oncol. 2010;36:509–16.

29. Zhang JF, Qu LS, Qian XF, Xia BL, Mao ZB, Chen WC. Nuclear transcription factor CDX2 inhibits gastric cancer-cell growth and reverses epithelial-to-mesenchymal transition in vitro and in vivo. Mol Med Rep. 2015;12:5231–8.

30. Zhang JF, Zhang JG, Kuai XL, Zhang H, Jiang W, Ding WF, et al. Reactivation of the homeotic tumor suppressor gene CDX2 by 5-aza–2′-deoxycytidine-induced demethylation inhibits cell proliferation and induces caspase-independent apoptosis in gastric cancer cells. Exp Ther Med. 2013;5:735–41.

31. Bai ZG, Ye YJ, Shen DH, Lu YY, Zhang ZT, Wang S. PTEN expression and suppression of proliferation are associated with Cdx2 overexpression in gastric cancer cells. Int J Oncol. 2013;42:1682–91.

32. Dang LH, Chen F, Knock SA, Huang EH, Feng J, Appelman HD, et al. CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45. Oncogene. 2006;25:2048–59.

33. Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, et al. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology. 2007;72:371–80.
34. Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S, Takano Y. The role of Reg IV gene and its encoding product in gastric carcinogenesis. Hum Pathol. 2010;41:59–69.
35. Tao HQ, He XJ, Ma YY, Wang HJ, Xia YJ, Ye ZY, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. Hum Pathol. 2011;42:1401–9.
36. Wang H, Hu L, Zang M, Zhang B, Duan Y, Fan Z, et al. REG4 promotes peritoneal metastasis of gastric cancer through GPR37. Oncotarget. 2016;7:27874–88.
37. Huang J, Yang Y, Yang J, Li X. Regenerating gene family member 4 promotes growth and migration of gastric cancer through protein kinase B pathway. Int J Clin Exp Med. 2014;7:3037–44.
38. Jin J, Lv H, Wu J, Li D, Chen K, Zhang F, et al. Regenerating family member 4 (Reg4) enhances 5-fluorouracil resistance of gastric cancer through activating MAPK/Erk/Bim signaling pathway. Med Sci Monit. 2017;23:3715–21.
39. Zhang XQ, Yu LT, Du P, Yin TQ, Zhang ZY, Xu Y, et al. Single-chain antibody against Reg4 suppresses gastric cancer cell growth and enhances 5-FU-induced cell death in vitro. Anticancer Agents Med Chem. 2019;19:610–9.
40. Zhang N, Chai DD, Du HF, Li KS, Xie WG, Li XW, et al. Expression of Reg IV and SOX9 and their correlation in human gastric cancer. BMC Cancer. 2018;18:344.
41. Yasui W, Oue N, Sentani K, Sakamoto N, Motoshita J. Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. Pathol Int. 2009;59:121–36.
42. Naito Y, Oue N, Hinoi T, Sakamoto N, Sentani K, Ohdan H, et al. Reg IV is a direct target of intestinal transcriptional factor CDX2 in gastric cancer. PLoS One. 2012;7:e47545.
43. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
44. Cisłó M, Filip AA, Arnold Offerhaus GJ, Ciseł B, Rawicz-Pruszyński K, Skierucha M, et al. Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology. Oncotarget. 2018;9:19427–42.
45. Koh I, Nosaka S, Sekine M, Sugimoto J, Hirata E, Kudo Y. Regulation of REG4 expression and prediction of 5-fluorouracil sensitivity by CDX2 in ovarian mucinous carcinoma. Cancer Genom Proteom. 2019;16:481–90.
46. Wang F, Xu L, Guo C, Ke A, Hu G, Xu X, et al. Identification of RegIV as a novel GLI1 target gene in human pancreatic cancer. PLoS One. 2011;6:e18434.
47. Nanakin A, Fukui H, Fujii S, Sekikawa A, Kanda N, Hisatsune H, et al. Expression of the REG IV gene in ulcerative colitis. Lab Invest. 2007;87:304–14.
48. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004;166:37–47.